VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19

Cao, Zhujun; Gao, Weiyi; Bao, Hong; Feng, Haiyan; Mei, Shuya; Chen, Peizhan; Gao, Yueqiu; Cui, Zhilei; Zhang, Qin; Meng, Xianmin; Gui, Honglian; Wang, Weijing; Jiang, Yimei; Song, Zijia; Shi, Yiqing; Sun, Jing; Zhang, Yifei; Xie, Qing; Xu, Yiping; Ning, Guang; Gao, Yuan; Zhao, Ren

doi:10.1056/nejmoa2208822

Public

VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19

Published in New England Journal of Medicine • Dec 28, 2022

Authors:

Zhujun Cao

Weiyi Gao

Hong Bao

Abstract

BACKGROUND: Nirmatrelvir-ritonavir has been authorized for emergency use by many countries for the treatment of coronavirus disease 2019 (Covid-19). However, the supply falls short of the global demand, which creates a need for more options. VV116 is an oral antiviral agent with potent activity agai...

Subject

Ritonavir

Hazard ratio

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!